Rheumatoid Arthritis | Treatment Algorithms | Claims Data Analysis | US | 2021

Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs (cDMARDs), such as methotrexate. For patients who fail cDMARD treatment, or exhibit an inadequate response, the U.S. market is crowded with efficacious biologics and targeted oral therapies, including blockbuster TNF-alpha inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) as well as non-TNF-alpha inhibitors such as BMS’s Orencia and Roche’s Actemra, and the oral JAK inhibitors, Xeljanz (Pfizer), Olumiant (Eli Lilly), and Rinvoq (AbbVie). Indeed, the FDA approval of Rinvoq has increased competition within the JAK class and among the non-TNF biologics, and has further expanded physicians’ treatment armamentarium.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed RA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed RA patients?
• How have non-TNF biologics and JAK inhibitors been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of RA patients receive drug therapy within three years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within three years of diagnosis?
• What percentage of RA patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: AbbVie, Amgen, Biogen, BMS, Eli Lilly, Janssen, Pfizer, Roche, Regeneron, Sanofi, UCB.

Key drugs: Actemra, biosimilar infliximab, Cimzia, Enbrel, Humira, Kevzara, Olumiant, Orencia, Remicade, Rinvoq, Rituxan, Simponi, Simponi Aria, Xeljanz.